The most common malignancy of exocrine pancreas is pancreatic ductal cancer (PDC). PDC is one of the most aggressive cancers. For the majority of patients, it remains a lethal disease, and is the 4th leading cause of cancer death in Europe. [..] READ MORE
To identify metabolic vulnerabilities in cancer is of a major importance to better understand the dependence of cancer cells on certain metabolic rewiring, and thus to identify new therapeutic targets. The majority of data provided in the past years relied on in vitro studies. [..] READ MORE
Leukemia stem cells (LSC) are the root of leukemia and known as the major cause of the relapse in leukemia patients. It is believed that therapeutic strategies based on targeting these drug resistance LSCs may ultimately result in eradication of leukemia and curing this disease. [..] READ MORE
Lung cancer is a common cause of cancer death. Progression free and overall survival is challenging to predict due to the variety of underlying genetic defects leading to cancer development. A number of gene mutations and subsequent downstream pathway alterations have been identified in oncogenesis of non-small cell lung cancer (NSCLC), [..] READ MORE
Endocytosis has recently emerged as a regulator of various pathways. Several of them are implicated in tumorogenesis. Vesicular trafficking of receptors can promote or down regulate pathways, depending on the type of vesicles (clathrin or caveolin dependent) or the end result of the endocytic process (recycling or degradation). [..] READ MORE
Background
The present study was to evaluate the chewers has the morphological and pathological changes among the chewers.
Methods
We analyzed the cytomorphological and the genotoxicity has been seen in chewers of exposed groups in building workers 30 building construction workers and number of age and sex matched controls. For each individual, 2000 exfoliated buccal cells were analyzed. [..] READ MORE
Hi!
We're here to answer your questions!
Send us a message via Whatsapp, and we'll reply the moment we're available!